MDGL Q2 2022 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$70M

Net Income

-$71M

EPS (Diluted)

$-4.14

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$57M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$216M

Total Liabilities

$133M

Stockholders' Equity

$84M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$70M	-$62M	-13.8%
Net Income	-$71M	-$62M	-14.7%